BACKGROUND AND PURPOSE: Reports of secondary high-grade glioma (HGG) in survivors of childhood cancer are scarce. The aim of this study was to review the pattern of diagnosis, the treatment, and outcome of secondary pediatric HGG. PATIENTS AND METHODS: We performed a multi-center retrospective study among the 17 paediatric institutions participating in the Canadian Pediatric Brain Tumour Consortium (CPBTC). RESULTS: We report on 18 patients (14 males, 4 females) treated in childhood for a primary cancer, who subsequently developed a HGG as a second malignancy. All patients had previously received radiation therapy +/- chemotherapy for either acute lymphoblastic leukaemia (n=9) or solid tumour (n=9). All HGG occurred within the previous radiation fields. At the last follow-up, 17 patients have died and the median survival time is 9.75 months. CONCLUSION: Although aggressive treatment seems to provide sustained remissions in some patients, the optimal management is still to be defined. Further documentation of such cases is necessary in order to better understand the pathogenesis, the natural history and the prevention of these tumours.
BACKGROUND AND PURPOSE: Reports of secondary high-grade glioma (HGG) in survivors of childhood cancer are scarce. The aim of this study was to review the pattern of diagnosis, the treatment, and outcome of secondary pediatric HGG. PATIENTS AND METHODS: We performed a multi-center retrospective study among the 17 paediatric institutions participating in the Canadian Pediatric Brain Tumour Consortium (CPBTC). RESULTS: We report on 18 patients (14 males, 4 females) treated in childhood for a primary cancer, who subsequently developed a HGG as a second malignancy. All patients had previously received radiation therapy +/- chemotherapy for either acute lymphoblastic leukaemia (n=9) or solid tumour (n=9). All HGG occurred within the previous radiation fields. At the last follow-up, 17 patients have died and the median survival time is 9.75 months. CONCLUSION: Although aggressive treatment seems to provide sustained remissions in some patients, the optimal management is still to be defined. Further documentation of such cases is necessary in order to better understand the pathogenesis, the natural history and the prevention of these tumours.
Authors: John DeSisto; John T Lucas; Ke Xu; Andrew Donson; Tong Lin; Bridget Sanford; Gang Wu; Quynh T Tran; Dale Hedges; Chih-Yang Hsu; Gregory T Armstrong; Michael Arnold; Smita Bhatia; Patrick Flannery; Rakeb Lemma; Lakotah Hardie; Ulrich Schüller; Sujatha Venkataraman; Lindsey M Hoffman; Kathleen Dorris; Jean M Mulcahy Levy; Todd C Hankinson; Michael Handler; Arthur K Liu; Nicholas Foreman; Rajeev Vibhakar; Kenneth Jones; Sariah Allen; Jinghui Zhang; Suzanne J Baker; Thomas E Merchant; Brent A Orr; Adam L Green Journal: Nat Commun Date: 2021-09-20 Impact factor: 17.694
Authors: Daniel C Bowers; Paul C Nathan; Louis Constine; Catherine Woodman; Smita Bhatia; Karen Keller; Lisa Bashore Journal: Lancet Oncol Date: 2013-07 Impact factor: 41.316
Authors: Aleksandra Napieralska; Aleksandra Krzywon; Agnieszka Mizia-Malarz; Joanna Sosna-Zielińska; Ewa Pawłowska; Małgorzata A Krawczyk; Katarzyna Konat-Bąska; Aneta Kaczorowska; Anna Dąbrowska; Maciej Harat Journal: Cancers (Basel) Date: 2021-04-24 Impact factor: 6.639